World's most expensive drug brings in $186M for Novartis in Q4

Zolgensma, the world's most expensive drug, brought in $186 million for Novartis in the fourth quarter, beating analysts expectations, STAT reported. 

The one-time gene therapy treatment is priced at $2.1 million and is designed to treat spinal muscular atrophy in infants. 

Novartis said about 200 patients have been treated with Zolgensma since it launched last June, according to STAT

The drug is covered for 97 percent of patients with commercial plans; 50 percent of Medicaid patients are covered.

Read the full article here

More articles on pharmacy:
Drug shortages update: 5 things to know
Grocery store pharmacies across the country finding it harder to stay in business
AbbVie to donate $1M of drug China says will combat coronavirus

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Content

Featured Webinars

Featured Whitepapers